We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

AREC Arecor Therapeutics Plc

0.00 (0.00%)
24 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Arecor Therapeutics Plc LSE:AREC London Ordinary Share GB00BMWLM973 ORD GBP0.01
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 120.00 8 01:00:00
Bid Price Offer Price High Price Low Price Open Price
115.00 125.00 120.00 120.00 120.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 5.72M -8.55M -0.2793 -4.30 36.75M
Last Trade Time Trade Type Trade Size Trade Price Currency
11:27:33 O 8 120.889 GBX

Arecor Therapeutics (AREC) Latest News

Arecor Therapeutics (AREC) Discussions and Chat

Arecor Therapeutics Forums and Chat

Date Time Title Posts
27/2/202409:01Current weakness-

Add a New Thread

Arecor Therapeutics (AREC) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2024-06-24 10:27:35120.8989.67O

Arecor Therapeutics (AREC) Top Chat Posts

Top Posts
Posted at 24/6/2024 09:20 by Arecor Therapeutics Daily Update
Arecor Therapeutics Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker AREC. The last closing price for Arecor Therapeutics was 120p.
Arecor Therapeutics currently has 30,626,986 shares in issue. The market capitalisation of Arecor Therapeutics is £36,752,383.
Arecor Therapeutics has a price to earnings ratio (PE ratio) of -4.30.
This morning AREC shares opened at 120p
Posted at 10/6/2024 12:27 by stupidboypike
sn "At least she's honest about it" that is probably the only positive, together with the recovering share price, which surprises me to be honest.

Best regards SBP
Posted at 10/6/2024 08:19 by stupidboypike
I'm not one for conspiracy theories but you would swear this RNS was written to get the share price down, in summary:

We are running out of cash, we don't know how to get more cash, we need a lot more cash (and time) to get interest in our biggest asset.

This is either incompetence on a biblical scale or deliberate. As a long term patient shareholder I am not happy this morning.

Best regards SBP
Posted at 10/6/2024 08:19 by henley2
CEO showing that she has no clue as to how to run a listed company.
It was obvious from the results that more money was required.
She should have raised after the good news from AT278 trial.
All today’s statement has done is crashed the share price, resulting in a lower price prior to the fundraising.
Posted at 16/5/2024 07:13 by jonesy100
Great progress but the going concern section is a bucket of cold water, confirming what we already had worked out. They need at least one more significant raise on the path to sustainability. Given the bombed out share price, I hope they can do it without too much dilution. We will find out soon enough I imagine. I am optimistic long term.
Posted at 28/2/2024 11:14 by stupidboypike
We have also been promised initial results of the AT278 trial in H1 this year. The last time we got some AT278 results it triggered the share price going from 220 to 400 in very short order, so as usual, "you pays your money and you takes your choice"

Best regards SBP
Posted at 27/2/2024 13:55 by jones1961
Please don't waste your time here Supernumerary. Arecor IPO was at 2.20, it hit a high of above 4 pounds, and was still above IPO price 9 months ago...I believe it is just what I say it is
Posted at 27/2/2024 11:40 by stupidboypike
Jones1961 many thanks for that information, it's very helpful. Like you I believe that this price represents an extraordinary opportunity, but I am fully invested. Best regards SBP
Posted at 24/1/2024 09:52 by mdchand

Trinity Delta view: Sanofi’s acquisition of INBRX-101 fits in with its portfolio growth strategy and its focus and reputation in rare diseases, and the $1.7bn+ deal value underscores INBRX-101’s attractiveness. For Arecor this is further commercial validation for its formulation expertise and ability to create clearly differentiated assets. INBRX-101 is Arecor’s second most advanced partnered asset, behind biosimilar AT220 (believed to be Fresenius Kabi’s tocilizumab) which launched in Europe in H223; both emerged from a technology formulation partnership. Such partnerships are a low-risk business model generating nearterm revenues; Arecor receives research fees from day one of any formulation development collaboration under which it reformulates and develops optimised versions of a partner’s own products or product candidates. Should these convert to licences, as with AT220 and INBRX-101, there is potential for meaningful financial upside via milestones and future commercialisation income (royalties or similar). For more detail on Arecor’s investment case see our November 2023 Outlook. Our valuation remains £179m, equivalent to 583p per share.
Posted at 04/12/2023 13:16 by 127tolmers
As foreshadowed in the TD report which calculated potential values of such a deal:

Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces a co-development and exclusive licence option agreement with a leading global medical products company for a high-value, ready-to-dilute (“RTD”) oncology product from Arecor’s in-house Specialty Hospital pipeline.

Under the terms of the agreement, Arecor and its partner will conduct further co-development and regulatory work with Arecor eligible to receive potential developmental milestones. The agreement includes an option for the partner to be granted an exclusive, worldwide license to further develop and commercialise the product, with Arecor eligible to receive milestones and royalty payments.

Arecor has developed a proprietary RTD form of a lyophilized powder product using its formulation technology platform, Arestat™. This novel, liquid, RTD formulation of an existing ‘blockbuster’ oncology therapy has the potential to offer significant advantages to the current product by replacing a lengthy, resource intensive reconstitution process, promoting safe medical practices and simplifying care with reduced patient chair time.
Posted at 29/11/2023 10:10 by stupidboypike
The lovely thing about these deals is there is no risk, the customer pays for development ( I'm sure with a small profit margin added) and if it's successful we get income, if not we lose nothing. They have added 11 since the IPO, can't help thinking our share price should be higher. Even if our blockbuster insulins fail to delight, I think these partnerships in time will make Arecor a very profitable company.
Might add a few in due course. Best regards SBP
Arecor Therapeutics share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock